• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of openrheumatoljLink to Publisher's site
Open Rheumatol J. 2011; 5: 107–114.
Published online Dec 30, 2011. doi:  10.2174/1874312901105010107
PMCID: PMC3263474
Suppl 1

The Synovium in Rheumatoid Arthritis

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease targeting multiple joints. The synovium is the primary site of the inflammatory process, which if untreated leads to irreversible damage to the adjacent cartilage and bone. It is now well established that autoantibodies that are characteristic of RA, including rheumatoid factor (RF) and anti-citrulluninated protein antibodies (ACPA), are present before clinical disease onset. Studies in both humans and animal models are beginning to provide new insights into how this asymptomatic autoimmunity evolves into an inflammatory process that is localized in the synovium.

Once RA synovitis established, a number of amplification mechanisms serve to sustain the process leading to the persistence of the disease. These mechanisms include engagement of the resident mesenchymal cells and the establishment of ectopic lymphoid structures in the synovium, although the relationship between these lymphoid structures and the presence of RA autoantibodies remains unclear.

An enhanced understanding of the mechanisms that initiate and sustain RA synovitis offers unprecedented opportunities for therapeutics, and ultimately prevention strategies.

Keywords: Rheumatoid, synovium, innate, lymphoid neogenesis.

INTRODUCTION

The transition from normal to non-specific inflammatory synovium and subsequently to established rheumatoid arthritis synovium is the result of a break in immune tolerance both systemically and at the level of the synovial tissue. The presence of circulating ACPA and RF years prior to the onset of clinical symptoms [1, 2] and early histological changes in the (presumed) unaffected joints of RA patients [3, 4] indicates that the early stages of this immune tolerance breakdown are subclinical. The importance of mediators of innate immunity in initiating synovial responses is being increasingly recognized. Recent progress has been made in elucidating the mechanisms involved in bridging the innate and adaptive immune systems leading to persistent synovitis, however our understanding of these mechanisms is still incomplete. This review will describe the main histopathological and immunohistologic features of RA synovitis, and will address some potentially important mechanisms that may facilitate the initiation and progression of rheumatoid arthritis synovitis.

PRE-CLINICAL STAGE OF RA

Circulating autoantibodies to citrullinated proteins (ACPA) can be detected several years prior to the onset of joint symptoms [1, 2] and examination of pre-disease cohorts of patients at risk for future RA has suggested a progression in the fine specificity of these responses consistent with epitope spreading [5]. This phenomenon has also been demonstrated in other autoimmune disorders such as systemic lupus erythematosus [6]. Citrullination itself is not unique to RA tissues, and indeed is a normal physiological process. While the source of the citrullinated protein autoantigens in established RA appears to be in the synovium [7, 8], extra-articular sites such as the lungs [9], or skin [10], are also potential sources. Isoforms of peptidylarginine deiminase (PAD), the enzyme responsible for post-translational conversion of arginine to citrulline in peptides, are found in a variety of cells and tissues [11-17], however to date only PAD2 and PAD4 have been found in synovium [7, 18]. PAD4 expression seems to be more specific for RA tissue, however the expression of both PAD2 and PAD 4 correlate with the degree of inflammation. Thus the development of immune responses to citrullinated proteins as indicated by the presence of ACPAs is highly suggestive of a break in immune tolerance that precedes the onset of clinically detectable synovitis.

NON-SPECIFIC SYNOVITIS, IMMUNE COMPLEXES AND INNATE IMMUNITY

Studies of the earliest stages of synovitis have mostly relied on animal models of rheumatoid-like inflammatory arthritis and although the direct application/attribution to human disease should be interpreted with some caution, these studies provide valuable insights into early pathogenesis. In the G6PI (KBxN) immune transfer mouse model of rheumatoid arthritis, components of the innate immune system including mast cells [19, 20], complement [21], Fc receptors [22], and cytokines such as IL-1 and TNFα [23] are critical for the development of synovitis. In this model, the formation of immune complexes appears to be an important initial step to allow pathogenic autoantibodies access to the synovium [24]. FCRγ-expressing cells in inflamed synovium may sense these circulating immune complexes leading to an increased vasopermeability preferentially in the distal extremities. On this basis, it is proposed that distal extremity vessels may have unique properties and that the increased vasopermeability may also have an amplifying function in the early stages of synovitis allowing influx of inflammatory cells into the joint tissues. It is well known that immune complexes are present in blood and synovial fluid of patients with established RA, but their role in the early stages of the disease is less clear. It has been shown that in a significant proportion of ACPA positive RA patients these circulating immune complexes contain citrullinated fibrinogen [25]. Immune complexes and citrullinated fibrinogen co-localize with complement component C3 in pannus tissue suggesting immune complex deposition and complement activation may lead to ongoing synovitis [25]. Recently, Monach et al. demonstrated that immune complexes deposited in synovium target a wide range of proteins some of which are histones and relatively specific for RA [26].

The potential importance of immune complexes in initiating human disease is supported by an illustrative case report which describes the progression of an initially asymptomatic individual who was ACPA positive, and who subsequently developed synovitis [27]. Although anti-CCP antibodies preceded joint symptoms, the development of antibodies to citrullinated fibrinogen coincided with the appearance of joint symptoms. On synovial biopsy of an affected knee performed soon after symptom onset, the lining layer was markedly abnormal whereas the sublining layer showed a histologically normal vascular pattern, and minimal if any increased cellularity. In the lining layer there was evidence of immune deposits of IgG, IgA, C3, and fibrin which co-localized with intra-cellular citrullinated proteins, and with widespread lining cell apoptosis (Fig. 11). This supports the hypothesis that pre-existing ACPA may access synovial tissue early in disease perhaps at the time of non-specific synovitis onset and that the synovial lining layer may be the primary target of the initial immune processes. It can be further speculated that the immune mechanisms generating ACPA are then amplified with continued exposure to citrullinated synovial antigens. In a similar case series of very early arthritis with a mean disease duration less than 4 weeks, perivascular CD3 and CD4 T cells and a mild superficial infiltration of lymphocytes and macrophages were found, however there were no aggregates and vascularity was normal, again suggesting superficial structures such as the lining layer may be a primary site for disease pathogenesis [28].

Fig. (1)
Synovial tissue analysis of biopsy material obtained from a symptomatic knee joint shortly after onset of articular symptoms. A) H&E light microscopy showing marked disruption of the synovial lining cell layer. The lining cells appear to be floating ...

DENDRITIC CELLS AND INNATE IMMUNITY IN RA SYNOVITIS

Dendritic cells (DC) are key players in innate immunity and may initiate and/or perpetuate synovitis by presenting arthritogenic antigens to components of the adaptive immune system [29-31]. Activation and maturation of DC occurs after exposure to multiple triggers including viral and bacterial products, cytokines, immune complexes, multiple endogenous ligands, and even disruption of cell-cell contact [32] and hypoxia [33]. Myeloid DC (mDC), and the more immature plasmacytoid DC (pDC) express distinct patterns of chemokine receptors and Toll-like receptors (TLR) [29, 34]. Both mDC and pDC are present in inflamed synovial tissue, and are not specific to RA [35-37]. However the number of pDC is higher in RA synovium compared to OA synovium, particularly in synovium from patients who are RF or ACPA positive. This observation is consistent with the suggestion that pDC may be involved in the synovial immune responses leading to the local formation of RA autoantibodies. In RA synovium, DC are located in primarily in the sublining tissues near aggregates of CD3 and CD8 cells [36], and adjacent to blood vessels [35]. Synovial pDC retain an immature phenotype and express IL-18 and IL-15, which may contribute to synovial inflammation and further DC recruitment, whereas synovial mDC produce IL-23 which may promote Th17 cell expansion [36]. The proportion of mature mDC increases with increasing grade of inflammation [37], possibly reflecting ongoing recruitment and activation of DC in persistent disease.

FIBROBLAST-LIKE SYNOVIOCYTES AS MEDIATORS OF INNATE IMMUNITY IN RA SYNOVITIS

RA fibroblast-like synoviocytes (FLS) express several TLR, suggesting they may contribute to the innate immune responses initiating and/or perpetuating RA synovitis. TLR3 and TLR4 in particular are highly expressed in RA synovium, even at an early stage of disease, and are found predominantly in the lining layer, occasionally extending into the sublining and perivascular areas [38]. TLR3 stimulation of RA FLS leads to increased expression of inflammatory cytokines such as IL-6, and to matrix degrading enzymes such as MMP3 and MMP13 [38]. A number of endogenous ligands stimulate TLR pathways in RA FLS [39], and can thus serve to activate these cells.

TRANSITION FROM EARLY NON-SPECIFIC SYNOVITIS TO ESTABLISHED RA SYNOVITIS

Key histological features of RA including synovial lining layer hypertrophy, sublining infiltration with mononuclear cells, increased vascularity and fibrin deposition are seen in patients reporting as little as 6 weeks or less of symptoms and in the unaffected joints of patients with active synovitis [3, 4], whereas organized lymphoid follicles and pannus tissue are features generally associated with established RA synovium (Fig. 22). As previously described, abnormalities of the synovial lining layer may be a very early feature of synovitis. Even in early clinical disease, the surface of the lining layer is often covered with fibrin deposits generated from the activation of the fibrinolytic system by synovial fluid. Indeed, the lining layer may be completely replaced by a fibrin cap, and in highly inflamed tissues this fibrin can extend deep into the sublining layers. In very early disease the sublining infiltrates may be minimal or modest [27, 28]. At this stage, macrophages [3], and an infiltration by natural killer cells has been described [40]. Diffuse mononuclear infiltrates and small lymphoid aggregates are seen in both early and late RA. However, as discussed in detail below, aggregates resembling lymphoid follicles with germinal centers are typically seen only in well established disease. The synovium obtained from ACPA positive RA patients tends to have more ectopic germinal centers and reduced fibrosis compared to synovium from ACPA negative patients, regardless of disease duration [41, 42], although other studies could not confirm these observations [43-45]. Pannus, the highly destructive tissue present at the interface between synovium, cartilage, and bone is a characteristic feature of erosive RA and contains large numbers of macrophages and fibroblasts that express high levels of proteases. Osteoclasts derived from pannus tissue can be detected at the interface of bone and cartilage (Fig. 33).

Fig. (2)
Histopathology of RA synovitis. (A) lymphoid aggregate; (B) Diffuse lymphocytes infiltrate; (C) Hyperplasia of the lining layer; (D) Fibrin cap replacing a denuded lining layer.
Fig. (3)
Interface between pannus tissue and bone in a patient with RA. (A) the synovial lesion is invading the adjacent bone. (B) Staining for tartrate resistant acid phosphatase in the circled area demonstrates the presence of osteoclasts.

Vascular patterns are also established early in disease and may serve to distinguish RA from other non-RA arthropathies [46, 47]. In established RA, vascular structures are prominent especially in the deep sublining areas presumably related to increased angiogenesis. Immature blood vessels can be found early in disease but are even more numerous in patients with erosive disease of longer duration indicating ongoing angiogenesis [48]. Despite evidence of angiogenesis, morphometric studies indicate there are relatively fewer blood vessels in sites adjacent to the expanded lining layer which when combined with the increased metabolic demands of the highly cellular structures, suggests relative hypoxia [49]. Hypoxia is a potent stimulus for the production of VEGF and other angiogenesis mediators which are highly expressed in inflamed RA synovium [50-52]. The vascular endothelium is activated by pro-inflammatory mediators to express adhesion molecules such as E-selectin, P-selectin, and ICAM1 that are involved in the recruitment of inflammatory cells. Synoviocytes also express adhesion molecules including VCAM1, VLA4, PECAM1 and ICAM1. These molecules are expressed equally in synovium from patients with early (<1 year symptoms) and late RA [53]. It is likely that adhesion molecules play a role in initiating and maintaining synovial infiltrates by recruiting inflammatory cells through the endothelium and then retaining inflammatory cells in the synovium through adherence to matrix cells and other synovial structures.

Histological comparisons of synovial tissue obtained from patients that have been matched for disease activity and treatment have shown no difference in cellular infiltration between those with early (<1 year) or late (>5 years) disease [54, 55]. Similarly, cytokine expression [56] and adhesion molecule expression [53] is similar between early and late disease. This supports the hypothesis that the earliest synovial pathology is subclinical, the duration of subclinical disease may be variable and that at the time of symptom onset, clinical assessment and subsequent tissue biopsy, the synovitis is already in a chronic stage [57]. In the absence of serial sampling of joints that progress from asymptomatic to minimally symptomatic to definite clinical synovitis to erosive synovitis it is difficult to assess the true histological progression of disease. Such studies are difficult to perform.

ECTOPIC LYMPHOID NEOGENESIS IN RA SYNOVIUM

One of the important unanswered questions in RA pathogenesis is how the systemic autoimmunity that precedes the clinical onset of RA becomes localized and amplified in the joints. To address this key question, a number of studies have aimed to develop a better understanding of ectopic lymphoid neogenesis, a process whereby lymphoid structures resembling those present in secondary lymphoid tissues become established in target tissues such as RA synovium. Research in this area has generated a number of important observations:

  1. Fully developed lymphoid aggregates with functional germinal centres are found in ~25% of RA synovial tissue samples, typically those derived from individuals with well established disease [44, 45, 58-62]. One hypothesis has suggested that the capacity to form these ectopic lymphoid structures in the synovium is an inherent property of the disease process in a subset of RA patients and one that is retained throughout the duration of the disease [60, 62]. Other viewpoints suggest that these structures are a non-specific reflection of the chronicity and severity of the disease, are not indicative of a unique immunopathologic process in a subset of RA patients [44, 45, 61] and may be reversible [43]. It should be added that ectopic lymphoid structures are by no means unique to rheumatoid synovitis, and have been well described in a spectrum of other chronic autoimmune diseases.
  2. Several key cytokines and chemokines have been shown to be involved in the formation of ectopic lymphoid structures in the synovium. These include CXCL13, CCL21, LTα,β [62-65]. The chemokine CXCL13 has been of particular interest since it is important in the recruitment of B cells, and was shown to be actively produced by antigen experienced synovial helper T cells [64].
  3. A recent detailed study of RA lymphoid aggregates indicates that synovial tissues with follicular structures characterized by the presence of follicular dendritic cell (FDC) networks express activation-induced cytidine deaminase (AID), the enzyme required for somatic hypermutation and class-switch recombination of Ig genes [59]. These structures were found to be spatially associated with plasma cells that produce ACPA. Moreover, elegant experiments where human RA synovium was transplanted into SCID mice provided compelling evidence that these AID positive FDC structures support ongoing production of class-switched ACPA which were detectable in the sera of the mice, without any requirement for further recruitment of immune cells, particularly B cells, into the lymphoid structures. While this study provides evidence that ectopic lymphoid structures in the RA synovium are functional and support autoantibody maturation and production, several other large studies have failed to demonstrate an association between ectopic lymphoid structures in the synovium and B cell autoimmunity in RA [43-45]. In particular, ectopic lymphoid neogenesis is described in RF and ACPA negative RA [43], and in psoriatic arthritis [58]. Thus, it remains a challenge to clearly define the pathogenic significance of these synovial lesions, which are characteristic although not specific for RA.

INTERACTIONS BETWEEN IMMUNE CELLS AND RESIDENT MESENCHYMAL CELLS IN THE SYNOVIUM

Irrespective of how the mononuclear cell infiltrate is arranged in the synovium, be it diffuse, aggregated, or with germinal centre formation, there is clearly close interaction between immune competent cells such as lymphocytes, macrophages, and DC with resident mesenchymal cells of the synovium such as FLS. The interactions between these cells are meditated by complex cytokine networks and by signaling events resulting from direct cell to cell contact. Much has been written about the former, as the study of cytokine effects on various cell types lends itself well to in vitro manipulation and experimentation. For example, the effects of key pro-inflammatory cytokines such as TNFa and IL1b have been exhaustively studied and exploited therapeutically. More recently, the recognition of the key pro-inflammatory role that the T cell cytokine IL-17 plays in RA synovitis, has generated similar investigative activity to better define the effects of this cytokine on cells in chronic inflammatory microenvironments such as the RA synovium (reviewed in [66, 67]).

In contrast to defining the effects of cytokines such as TNFa, IL-1b, and IL-17 on cell biology, the effects that are mediated by cell-cell contact are more subtle, and more difficult manipulate in vitro. The close in vivo juxtaposition of T cells, B cells, macrophages, dendritic cells, and FLS in the synovial microenvironment suggests that the signaling events mediated by direct cell-cell contact between these cells likely involve multiple partners simultaneously, a situation that is difficult to simulate in vitro. Nevertheless, an interesting recent study demonstrated that in vivo activated CD14+ monocytes derived from the inflamed joints of patients with active RA spontaneously and specifically promoted Th17, but not Th1 or Th2 responses, compared with resting CD14+ monocytes from the blood. These in vivo activated monocytes promoted Th17 responses in a cell-contact dependent manner, and unlike Th17 stimulation by monocytes that were in vitro activated with lipopolysaccharide, intracellular IL-17 expression was TNF-alpha- and IL-1beta-independent. These data suggest that newly recruited memory CD4 T cells can be induced to produce IL-17 after cell-cell interactions with activated monocytes in the synovium [68]. This mechanism may be particularly relevant in explaining the incomplete responses observed with TNFa inhibition and the recurrence of disease with withdrawal of therapy.

The interactions between immune/inflammatory cells and FLS are of particular interest since they are an important link between the inflammatory and destructive arms of RA synovitis. RA T cells, which have been shown to exhibit extensive features of premature senescence [69], aberrantly express the fractalkine (FKN) receptor CX3CR1 which interacts with FKN expressed on FLS. This interaction results in activation and enhanced survival of the T cells [70], as well as proliferation of the FLS [71]. A parallel interaction is mediated through the aberrant expression of natural-killer group 2, member D (NKG2D) and its ligand MIC expressed on FLS [72]. Such self-sustaining amplification loops between synovial T cells and FLS potentially plays a key role in the perpetuation of RA synovitis, while increasing its destructive potential.

Much has been learned over the past two decades about the biology of FLS and how they become “transformed” in the RA synovial microenvironment to become efficient matrix degrading cells that make a major contribution to the articular damage seen in RA joints. An important recent insight has been the identification of cadherin 11 as the adhesion molecule that mediates the homotypic aggregation of FLS in the synovial lining layer [73-75]. These studies have clearly shown that cadherin 11 is an important mediator of RA FLS invasiveness, and that inhibition of this molecule results in a dramatic amelioration to the articular damage caused by chronic synovitis. Additionally, SCID mouse studies have demonstrated the ability of human RA FLS to migrate and damage distal unaffected human cartilage in a process that may be facilitated by angiogenesis. Therapeutic exploitation of these observations may add substantially to the current armamentarium, which is focused primarily on inhibiting inflammatory mediators and cells rather than matrix degrading FLS.

CONCLUSIONS

Recent insights obtained from animal models and studies of early and established RA synovial tissues have suggested potential mechanisms by which normal immune tolerance is interrupted leading to autoimmunity (Fig. 44). A non-specific insult could potentially trigger local innate immunity heralding the onset of clinical synovitis. In the setting of autoimmunity this inflammation persists leading to the formation of organized lymphoid structures and angiogenesis which serve to sustain the inflammatory synovium. In time, mesenchymal transformation and osteoclastogenesis lead to the destructive lesions characteristic of established RA. This paradigm suggests steps at which targeted intervention has the potential to significantly alter the course of disease and identifies structures and mechanisms which may be predictive of disease outcome or treatment response.

Fig. (4)
Conceptual framework for the evolution of RA synovitis.

ACKNOWLEDGEMENT

None declared.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Nielen MM, van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6. [PubMed]
2. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9. [PubMed]
3. Kraan MC, Versendaal H, Jonker M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 1998;41(8):1481–8. [PubMed]
4. Pando JA, Duray P, Yarboro C, Gourley MF, Klippel JH, Schumacher HR. Synovitis occurs in some clinically normal and asymptomatic joints in patients with early arthritis. J Rheumatol. 2000;27(8):1848–54. [PubMed]
5. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58(10):3000–8. [PubMed]
6. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. [PubMed]
7. De RL, Nicholas AP, Cantaert T, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 2005;52(8):2323–30. [PubMed]
8. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 2004;50(11):3485–94. [PubMed]
9. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatol. 2007;46(1):70–5. [PubMed]
10. Tsuji Y, Akiyama M, Arita K, Senshu T, Shimizu H. Changing pattern of deiminated proteins in developing human epidermis. J Invest Dermatol. 2003;120(5):817–22. [PubMed]
11. Asaga H, Nakashima K, Senshu T, Ishigami A, Yamada M. Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J Leukoc Biol. 2001;70(1):46–51. [PubMed]
12. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer. 2009;9:40. [PMC free article] [PubMed]
13. Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res. 2007;32(2):251–6. [PMC free article] [PubMed]
14. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem. 2002;277(51):49562–8. [PubMed]
15. Urano Y, Watanabe K, Sakaki A, et al. Immunohistochemical demonstration of peptidylarginine deiminase in human sweat glands. Am J Dermatopathol. 1990;12(3):249–55. [PubMed]
16. Ying S, Dong S, Kawada A, et al. Transcriptional regulation of peptidylarginine deiminase expression in human keratinocytes. J Dermatol Sci. 2009;53(1):2–9. [PubMed]
17. Zhang J, Dai J, Zhao E, et al. cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type VI. Acta Biochim Pol. 2004;51(4):1051–8. [PubMed]
18. Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007;56(11):3541–53. [PubMed]
19. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689–92. [PubMed]
20. Nigrovic PA, Binstadt BA, Monach PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci USA. 2007;104(7):2325–30. [PMC free article] [PubMed]
21. Monach PA, Verschoor A, Jacobs JP, et al. Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. Arthritis Rheum. 2007;56(9):2968–74. [PMC free article] [PubMed]
22. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16(2):157–68. [PubMed]
23. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196(1):77–85. [PMC free article] [PubMed]
24. Binstadt BA, Patel PR, Alencar H, et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol. 2006;7(3):284–92. [PubMed]
25. Zhao X, Okeke NL, Sharpe O, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R94. [PMC free article] [PubMed]
26. Monach PA, Hueber W, Kessler B, et al. A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci USA. 2009;106(37):15867–72. [PMC free article] [PubMed]
27. Willemze A, Ioan-Facsinay A, El-Gabalawy H. Anti-citrullinated protein antibody response associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis. J Rheumatol. 2008;35(11):2282–4. [PubMed]
28. Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients. J Rheumatol. 2004;31(7):1281–5. [PubMed]
29. Lutzky V, Hannawi S, Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther. 2007;9(4):219. [PMC free article] [PubMed]
30. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007;7(1):19–30. [PubMed]
31. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–26. [PubMed]
32. Jiang A, Bloom O, Ono S, et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity. 2007;27(4):610–24. [PMC free article] [PubMed]
33. Bosco MC, Puppo M, Blengio F, et al. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology. 2008;213(9-10):733–49. [PubMed]
34. Vanbervliet B, driss-Vermare N, Massacrier C, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med. 2003;198(5):823–30. [PMC free article] [PubMed]
35. Cavanagh LL, Boyce A, Smith L, et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther. 2005;7(2):R230–R240. [PMC free article] [PubMed]
36. Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol. 2008;172(4):940–50. [PMC free article] [PubMed]
37. Takakubo Y, Takagi M, Maeda K, et al. Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis. J Rheumatol. 2008;35(10):1919–31. [PubMed]
38. Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008;58(12):3684–92. [PubMed]
39. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol. 2005;233(2):90–6. [PubMed]
40. Tak PP, Kummer JA, Hack CE, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum. 1994;37(12):1735–43. [PubMed]
41. Cantaert T, Brouard S, Thurlings RM, et al. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheum. 2009;60(7):1944–56. [PubMed]
42. van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum. 2008;58(1):53–60. [PubMed]
43. Canete JD, Celis R, Moll C, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(5):751–6. [PubMed]
44. Cantaert T, Kolln J, Timmer T, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol. 2008;181(1):785–94. [PubMed]
45. Thurlings RM, Wijbrandts CA, Mebius RE, et al. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum. 2008;58(6):1582–9. [PubMed]
46. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003;30(2):260–8. [PubMed]
47. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999;42(7):1481–4. [PubMed]
48. Izquierdo E, Canete JD, Celis R, et al. Immature blood vessels in Rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One. 2009;4(12):e8131. [PMC free article] [PubMed]
49. Stevens CR, Blake DR, Merry P, Revell PA, Levick JR. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. 1991;34(12):1508–13. [PubMed]
50. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002;46(10):2587–97. [PubMed]
51. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001;44(7):1540–4. [PubMed]
52. Muz B, Khan MN, Kiriakidis S, Paleolog EM. Hypoxia The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther. 2009;11(1):201. [PMC free article] [PubMed]
53. Tak PP, Thurkow EW, Daha MR, et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol. 1995;77(3):236–42. [PubMed]
54. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis. 2000;59(12):945–53. [PMC free article] [PubMed]
55. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997;40(2):217–25. [PubMed]
56. Smeets TJ, Dolhain RJ, Breedveld FC, Tak PP. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol. 1998;186(1):75–81. [PubMed]
57. Tak PP. Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis? Best Pract Res Clin Rheumatol. 2001;15(1):17–26. [PubMed]
58. Canete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis. 2007;66(6):720–6. [PMC free article] [PubMed]
59. Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009;6(1):e1. [PMC free article] [PubMed]
60. Klimiuk PA, Goronzy JJ, Bjor NJ, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol. 1997;151(5):1311–9. [PMC free article] [PubMed]
61. Manzo A, Pitzalis C. Lymphoid tissue reactions in rheumatoid arthritis. Autoimmun Rev. 2007;7(1):30–4. [PubMed]
62. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001;167(2):1072–80. [PubMed]
63. Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol. 2005;35(5):1347–59. [PubMed]
64. Manzo A, Vitolo B, Humby F, et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 2008;58(11):3377–87. [PubMed]
65. Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum. 2007;56(8):2492–502. [PubMed]
66. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98. [PubMed]
67. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):549–53. [PubMed]
68. Evans HG, Gullick NJ, Kelly S, et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci USA. 2009;106(15):6232–7. [PMC free article] [PubMed]
69. Goronzy JJ, Henel G, Sawai H, et al. Costimulatory pathways in rheumatoid synovitis and T-cell senescence. Ann N Y Acad Sci. 2005;1062:182–94. [PubMed]
70. Sawai H, Park YW, Roberson J, Imai T, Goronzy JJ, Weyand CM. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2005;52(5):1392–401. [PubMed]
71. Sawai H, Park YW, He X, Goronzy JJ, Weyand CM. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 2007;56(10):3215–25. [PubMed]
72. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA. 2003;100(16):9452–7. [PMC free article] [PubMed]
73. Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol. 2006;168(5):1486–99. [PMC free article] [PubMed]
74. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315(5814):1006–10. [PubMed]
75. Valencia X, Higgins JM, Kiener HP, et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med. 2004;200(12):1673–9. [PMC free article] [PubMed]

Articles from The Open Rheumatology Journal are provided here courtesy of Bentham Science Publishers

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...